Concord Biotech Limited Operating Cash Flow for the year ending March 31, 2025: USD 28.95 M

Concord Biotech Limited Operating Cash Flow is USD 28.95 M for the year ending March 31, 2025, a -9.03% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Concord Biotech Limited Operating Cash Flow for the year ending March 31, 2024 was USD 31.83 M, a 6.33% change year over year.
  • Concord Biotech Limited Operating Cash Flow for the year ending March 31, 2023 was USD 29.93 M, a 9.54% change year over year.
  • Concord Biotech Limited Operating Cash Flow for the year ending March 31, 2022 was USD 27.32 M, a 19.94% change year over year.
  • Concord Biotech Limited Operating Cash Flow for the year ending March 31, 2021 was USD 22.78 M, a 10.87% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities